Ezh2, a novel target in detection and therapy of breast cancer

OncoTargets and Therapy

Volumn 10, Issue , 2017, Pages 2685-2687

  Pourakbar, Sarah ^a,b   Pluard, Timothy J ^c   Aaccurso, Anthony D ^a   Farassati, Faris ^a,c  

^a Kansas City Veterans Aaffairs Medical Center   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c Saint Lluke s Cancer Iinstitute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR EZH2; UVOMORULIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; NONHUMAN; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL PREDICTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 85019681633     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S138777     Document Type: Article

References (18)

1. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics. 2013. CA Cancer J Clin. 2014;64(1):52-62.
2. Martins D, Beca F, Schmitt F. Metastatic breast cancer: mechanisms and opportunities for cytology. Cytopathology. 2014;25(4):225-230.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics. 2013. CA Cancer J Clin. 2013;63(1):11-30.
4. Beaumont T, Leadbeater M. Treatment and care of patients with metastatic breast cancer. Nurs Stand. 2011;25(40):49-56.
5. Wang X, Hu B, Shen H, et al. Clinical and prognostic relevance of EZH2 in breast cancer: a meta-analysis. Biomed Pharmacother. 2015;75:218-225.
6. Inari H, Suganuma N, Kawachi K, et al. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions. BMC Cancer. 2017;17(1):160.
7. Guo S, Li X, Rohr J, et al. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features. Diagn Pathol. 2016;11:41.
8. Jang SH, Lee JE, Oh MH, et al. High EZH2 protein expression is associated with poor overall survival in patients with luminal a breast cancer. J Breast Cancer. 2016;19(1):53-60.
9. Lawrence CL, Baldwin AS. Non-canonical EZH2 transcriptionally activates RelB in triple negative breast cancer. PLoS One. 2016;11(10):e0165005.
10. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606-11611.
11. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006;12(4):1168-1174.
12. Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 2006;66(8):4095-4099.
13. Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27(58):7274-7284.
14. Moore HM, Gonzalez ME, Toy KA, et al. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Res Treat. 2013;138(3):741-752.
15. Zeidler M, Kleer CG. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol. 2006;37(5-7):219-223.
16. Alford SH, Toy K, Merajver SD, Kleer CG. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat. 2012;132(2):429-437.
17. Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res. 2013;32(1):70.
18. Holm K, Grabau D, Lövgren K, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol. 2012;6(5):494-506.